THE ROLE OF PCSK9 INHIBITORS IN HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASES

Authors

  • Lutfullayev Oltin Oybek ugli Asia International University, Bukhara, Uzbekistan Author

DOI:

https://doi.org/10.5281/zenodo.20187455

Keywords:

PCSK9 inhibitors, hyperlipidemia, cardiovascular diseases, LDL cholesterol, atherosclerosis, statins, liver dysfunction, lipid-lowering therapy.

Abstract

Atherosclerotic cardiovascular diseases remain the leading cause of mortality worldwide and represent a major global health burden. Low-density lipoprotein cholesterol plays a central role in the pathogenesis of atherosclerosis. Although statins have long been the cornerstone of lipid-lowering therapy, a considerable number of patients either do not achieve target lipid levels or develop intolerance. These limitations have stimulated the development of novel pharmacological approaches, among which PCSK9 inhibitors have emerged as one of the most promising strategies. This article analyzes the clinical efficacy, pharmacological mechanisms, and practical significance of PCSK9 inhibitors in the management of hyperlipidemia and prevention of cardiovascular diseases, with special attention to patients with hepatic dysfunction.

 

References

1.Sabatine M.S., Giugliano R.P., Keech A.C., et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017;376(18):1713–1722.

2.Schwartz G.G., Steg P.G., Szarek M., et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine. 2018;379(22):2097–2107.

3.Ference B.A., Ginsberg H.N., Graham I., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. European Heart Journal. 2017;38(32):2459–2472.

4.Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2020;41(1):111–188.

5.Grundy S.M., Stone N.J., Bailey A.L., et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. 2019;139:e1082–e1143.

6.Rosenson R.S., Hegele R.A., Fazio S. The Evolving Future of PCSK9 Inhibitors. Journal of the American College of Cardiology. 2018;72(3):314–329.

7.Stoekenbroek R.M., Kastelein J.J.P., Huijgen R. PCSK9 inhibition: the way forward in the treatment of dyslipidemia. BMC Medicine. 2015;13:258.

8.Seidah N.G., Awan Z., Chretien M., Mbikay M. PCSK9: A key modulator of cardiovascular health. Circulation Research. 2014;114(6):1022–1036.

9.Giugliano R.P., Pedersen T.R., Park J.G., et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with evolocumab. Lancet. 2017;390(10106):1962–1971.

10.Goldberg A.C., Leiter L.A., Stroes E.S., et al. Effect of Alirocumab on Lipids and Cardiovascular Events. The Lancet. 2015;385(9965):331–340.

Downloads

Published

2026-05-14